Medicenna Therapeutics Corp is facing a tough situation as its stock takes a hit.
In today's trading session, Medicenna Therapeutics Corp (MDNA.TO) is down 1.28%, raising concerns among investors due to a lack of recent positive news. With a market cap of about CA$35.99 million, the company is navigating a challenging landscape.
Investor takeaway: Investors should be cautious as Medicenna's stock struggles to gain traction, reflecting broader market sentiment and potential worries about its financial health.
Advertisement
Medicenna Therapeutics Corp
MDNA.TO
MDNA.TO
Medicenna Therapeutics Corp
WealthAwesomeMarket cap
$36.00M
52W high
$1.97
52W low
$0.34
1W change
+11.43%
Beta
1.89
Analyst Price Targets
Based on analyst covering MDNA
Wall Street analysts forecast MDNA stock price to rise 720.5% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$3.20
+720.5% Upside
Current Price
C$0.39
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on MDNA's historical volatility
30-Day Vol
38.0%
Annualized
90-Day Vol
68.6%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$0.33
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$0.37 | C$0.32 – C$0.42 |
| 60 trading days | C$0.35 | C$0.29 – C$0.42 |
| 90 trading days | C$0.33 | C$0.26 – C$0.41 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Medicenna's stock drops 1.28% in today's session
Currently priced at CA$0.39, Medicenna's market cap is CA$35.99 million, indicating investor caution in the biotech sector.
Bull case
Supporters of Medicenna might argue that the company's ongoing research and development efforts could lead to breakthroughs, especially with its MDNA11 and MDNA113 programs.
Bear case
However, the current decline raises doubts about investor confidence, particularly given the lack of significant news or developments to support the stock price.
Current Market Performance
Advertisement
Medicenna Therapeutics Corp's stock is down 1.28% today, closing at CA$0.39. This drop raises concerns among investors, especially considering the company's recent public offering, which may have diluted existing shares.
Investor Sentiment and Future Outlook
The absence of recent positive news about Medicenna has contributed to today's stock decline. Investors are likely weighing the company's potential against its current financial performance, particularly as it competes in the biotech landscape.
Understanding the Context
While Medicenna's innovative programs like MDNA11 and MDNA113 show promise, the current market reaction indicates that investors are looking for more tangible results. The lack of significant updates or breakthroughs may continue to impact the stock in the near term.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
